Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)

January 11, 2019 updated by: Merck Sharp & Dohme LLC

A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults

This study will determine whether at least one formulation of an experimental dengue vaccine (V180) is safe and causes an immune response.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

98

Phase

  • Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 49 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Selected Inclusion Criteria:

  • In good health
  • Voluntarily agrees to participate by giving written informed consent
  • Able to read, understand, and complete study questionnaires
  • Able to complete all scheduled visits and comply with study procedures
  • Access to a telephone
  • Agrees to avoid unusual, vigorous exercise from 72 hours before any dose of study vaccine/placebo through 15 days after that dose
  • Weighs ≥110 pounds (50 kg) and has a body mass index (BMI) of 19 to 32 kg/m^2
  • No fever (temperature ≥100.4°F/38.0°C) for 72 hours prior to vaccination
  • Females of reproductive potential agree to remain abstinent or to use 2 acceptable methods of birth control from enrollment through 6 weeks after the last dose of study vaccine/placebo

Selected Exclusion Criteria:

  • History of receiving any flavivirus vaccine (e.g. Japanese encephalitis, tick-borne encephalitis, or yellow fever) or planned receipt of any such vaccine during the study period
  • History of any flavivirus infection or serologic evidence of any flavivirus infection, including West Nile, dengue, yellow fever, Saint Louis encephalitis (if available), Kunjin, Murray Valley encephalitis, and Japanese encephalitis
  • History of residence for a cumulative period of >1 year in a country where dengue, Japanese encephalitis virus, or yellow fever virus is common
  • Planned travel to an area where dengue is common through 28 days after receiving the last dose of study vaccine/placebo
  • Known hypersensitivity to any component of the dengue vaccine
  • Abuse of drugs or alcohol within 12 months prior to screening
  • Pregnant or breastfeeding, or expecting to conceive in the time from enrollment through 6 weeks after the last dose of study vaccine/placebo
  • Positive serum test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), and/or hepatitis C antibody
  • Known, suspected, or a history of immunocompromise
  • History of malignancy within 5 years prior to enrollment
  • Poorly controlled diabetes mellitus
  • Use of any immunosuppressive therapy (except topical and inhaled/nebulized steroids)
  • Receipt of any licensed non-live vaccine within 14 days prior to the first dose of study vaccine/placebo or plans to receive a licensed non-live vaccine during the time between receiving the first dose and 28 days after receiving the last dose of study vaccine/placebo
  • Receipt of any licensed live vaccine within 30 days prior to the first dose of study vaccine/placebo or plans to receive a licensed live vaccine during the time between receiving the first dose and 28 after receiving the last dose of study vaccine/placebo
  • Received investigational drugs or vaccines within 2 months prior to the first dose of study vaccine/placebo
  • History of receiving 1 or more doses of an investigational dengue vaccine
  • Participation in another clinical study within 42 days prior to enrollment, or plans to participate in another clinical study from enrollment through 1 year after the last dose of study vaccine/placebo
  • Planned donation of eggs or sperm from the time of enrollment through 28 days after the last dose of study vaccine/placebo
  • Prior receipt of a blood transfusion or blood products within 6 months prior to the first dose of study vaccine/placebo
  • Hospitalization for acute illness within 3 months prior to the first dose of vaccine/placebo

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Biological: Placebo
Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
Experimental: Low-dose V180 with low-dose ISCOMATRIX™ adjuvant
Biological: Low-dose V180 with low-dose ISCOMATRIX™ adjuvant
Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Experimental: Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Biological: Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Experimental: Medium-dose Non-adjuvanted V180
Biological: Medium-dose V180 (non-adjuvanted)
Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
Experimental: Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant
Biological: Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant
Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Experimental: Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Biological: Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Experimental: Medium-Dose V180 with Alhydrogel™ adjuvant
Biological: Medium-dose V180 with Alhydrogel™ adjuvant
Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
Experimental: High-dose Non-adjuvanted V180
Biological: High-dose V180 (non-adjuvanted)
Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
Experimental: High-dose V180 with low-dose ISCOMATRIX™ adjuvant
Biological: High-dose V180 with low-dose ISCOMATRIX™ adjuvant
Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Experimental: High-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Biological: High-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Experimental: Low-dose V180 with high-dose ISCOMATRIX™ adjuvant
Biological: Low-dose V180 with high-dose ISCOMATRIX™ adjuvant
Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Experimental: Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant
Biological: Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant
Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Experimental: High-dose V180 with high-dose ISCOMATRIX™ adjuvant
Biological: High-dose V180 with high-dose ISCOMATRIX™ adjuvant
Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Seroconversion rate for each serotype
Time Frame: 28 days postdose 3 (Day 84)
28 days postdose 3 (Day 84)
Geometric mean titer (GMT) of virus neutralizing antibodies for each serotype
Time Frame: 28 days postdose 3 (Day 84)
28 days postdose 3 (Day 84)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Merck Sharp & Dohme LLC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 23, 2012

Primary Completion (Actual)

January 23, 2014

Study Completion (Actual)

December 11, 2014

Study Registration Dates

First Submitted

November 18, 2011

First Submitted That Met QC Criteria

November 18, 2011

First Posted (Estimate)

November 22, 2011

Study Record Updates

Last Update Posted (Actual)

January 15, 2019

Last Update Submitted That Met QC Criteria

January 11, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • V180-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dengue

Clinical Trials on Low-dose V180 with low-dose ISCOMATRIX™ adjuvant

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe